Physician profile
Ajay Varma
NPI 1841482106
$9,130.13
in general payments reported to CMS, 2019-2025
27 companies · $579 in 2025
The $579 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,687 · 2020: $893 · 2021: $1,206 · 2022: $1,290 · 2023: $1,574 · 2024: $902 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,325 · Travel and Lodging: $730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,324.90 |
| Travel and Lodging | $729.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertiflex, INC. | $1,808.77 | 2019 | |
| Medtronic, INC. | $1,412.14 | 2021-2025 | Venaseal, Catalyft Pl Expandable Interbody System, Synchromedii |
| Abbott Laboratories | $1,336.21 | 2020-2025 | Proclaim, Octrode |
| Nevro Corp. | $996.14 | 2019-2021 | |
| Boston Scientific Corporation | $987.15 | 2019-2025 | Emblem Mri S-Icd, General - Pain Management, Wavewriter Alpha Prime 16 |
| Si-Bone, INC. | $462.96 | 2019-2020 | |
| Spinefrontier, INC. | $351.04 | 2020-2025 | Inspan, Nanofuse, Sijfuse |
| Stryker Corporation | $337.87 | 2021 | |
| Spr Therapeutics, INC | $290.65 | 2020-2022 | |
| Nalu Medical, INC. | $285.92 | 2021-2024 | Nalu Neurostimulation System |
| Biotronik Nro, INC. | $273.09 | 2024 | Prospera |
| Medtronic USA, INC. | $152.34 | 2019 | |
| Foundation Fusion Solutions, LLC | $57.79 | 2023-2024 | |
| Vertos Medical, INC. | $50.36 | 2021-2022 | |
| Tersera Therapeutics LLC | $49.15 | 2024-2025 | Prialt |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $43.53 | 2024 | Inspire |
| Collegium Pharmaceutical, INC. | $29.20 | 2019-2023 | Belbuca |
| Merit Medical Systems INC | $28.92 | 2021-2022 | |
| Abbvie INC. | $28.30 | 2021-2023 | Qulipta |
| Bioventus LLC | $25.93 | 2021-2022 | |
| Grt US Holding, INC. | $24.93 | 2022 | |
| Zimmer Biomet Holdings, INC. | $22.40 | 2023 | Gel-One Cross-Linked Hyaluronate |
| Relievant Medsystems, INC. | $21.34 | 2023 | Intracept |
| Avanos Medical | $16.65 | 2022 | |
| Supernus Pharmaceuticals, INC. | $15.94 | 2019 | |
| Depuy Synthes Sales INC. | $11.10 | 2020 | |
| Stimwave Technologies Incorporated | $10.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Varma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.